Institution
Tokyo Metropolitan Komagome Hospital
Healthcare•Tokyo, Japan•
About: Tokyo Metropolitan Komagome Hospital is a healthcare organization based out in Tokyo, Japan. It is known for research contribution in the topics: Breast cancer & Cancer. The organization has 474 authors who have published 589 publications receiving 35532 citations. The organization is also known as: Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital.
Topics: Breast cancer, Cancer, Transplantation, Hematopoietic stem cell transplantation, Autoimmune pancreatitis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
5,679 citations
••
Harvard University1, University of Cambridge2, Mayo Clinic3, Okayama University4, Technische Universität München5, Dalhousie University6, University of Amsterdam7, Southampton General Hospital8, Tokyo Metropolitan Komagome Hospital9, Shinshu University10, Kanazawa University11, Kanazawa Medical University12, Kansai Medical University13, Seoul National University14, University College London15, Sapporo Medical University16, University of Verona17
TL;DR: This statement proposes a terminology scheme for the diagnosis of IgG4-related disease that is based primarily on the morphological appearance on biopsy, and advocates the use of strict criteria for accepting newly proposed entities or sites as components of the IgG 4- related disease spectrum.
2,041 citations
••
Fukuoka University1, McMaster University2, Japanese Foundation for Cancer Research3, Fox Chase Cancer Center4, National Institutes of Health5, University of Leeds6, University of Cincinnati7, University of Paris8, Katholieke Universiteit Leuven9, Shiga University of Medical Science10, Niigata University11, Seoul National University12, University of Erlangen-Nuremberg13, Tokyo Metropolitan Komagome Hospital14, University of Florida15, University of California, Los Angeles16, University of Vienna17, University of Innsbruck18, Northwick Park Hospital19, Karolinska Institutet20, Hokkaido University21, University of Helsinki22, Kyoto University23
TL;DR: The differences between Western and Japanese pathologists in the diagnostic classification of gastrointestinal epithelial neoplastic lesions can be resolved largely by adopting the proposed terminology, which is based on cytological and architectural severity and invasion status.
Abstract: Background—Use of the conventional Western and Japanese classification systems of gastrointestinal epithelial neoplasia results in large diVerences among pathologists in the diagnosis of oesophageal, gastric, and colorectal neoplastic lesions. Aim—To develop common worldwide terminology for gastrointestinal epithelial neoplasia. Methods—Thirty one pathologists from 12 countries reviewed 35 gastric, 20 colorectal, and 21 oesophageal biopsy and resection specimens. The extent of diagnostic agreement between those with Western and Japanese viewpoints was assessed by kappa statistics. The pathologists met in Vienna to discuss the results and to develop a new consensus terminology. Results—The large diVerences between the conventional Western and Japanese diagnoses were confirmed (percentage of specimens for which there was agreement and kappa values: 37% and 0.16 for gastric; 45% and 0.27 for colorectal; and 14% and 0.01 for oesophageal lesions). There was much better agreement among pathologists (71% and 0.55 for gastric; 65% and 0.47 for colorectal; and 62% and 0.31 for oesophageal lesions) when the original assessments of the specimens were regrouped into the categories of the proposed Vienna classification of gastrointestinal epithelial neoplasia: (1) negative for neoplasia/dysplasia, (2) indefinite for neoplasia/dysplasia, (3) non-invasive low grade neoplasia (low grade adenoma/ dysplasia), (4) non-invasive high grade neoplasia (high grade adenoma/ dysplasia, non-invasive carcinoma and suspicion of invasive carcinoma), and (5) invasive neoplasia (intramucosal carcinoma, submucosal carcinoma or beyond). Conclusion—The diVerences between Western and Japanese pathologists in the diagnostic classification of gastrointestinal epithelial neoplastic lesions can be resolved largely by adopting the proposed terminology, which is based on cytological and architectural severity and invasion status. (Gut 2000;47:251‐255)
1,940 citations
••
Teikyo University1, Hiroshima University2, Niigata University3, University of Tsukuba4, Saitama Medical University5, Tokyo Medical and Dental University6, University of Tokyo7, Japanese Foundation for Cancer Research8, Kyorin University9, Kyoto University10, National Defense Medical College11, Dokkyo Medical University12, Tohoku University13, Tokyo Metropolitan Komagome Hospital14, Osaka Medical College15, Kurume University16, International University of Health and Welfare17, Toho University18
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Abstract: Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.
1,709 citations
••
Kanazawa Medical University1, Kansai Medical University2, Kanazawa University3, Sapporo Medical University4, University of Toyama5, Okayama University6, Nagoya University7, Shinshu University8, Tokyo Metropolitan Komagome Hospital9, Tohoku University10, Kyushu University11, University of Tsukuba12, Kyoto University13, Keio University14, Kagoshima University15, Fujita Health University16, Nagoya City University17
TL;DR: The comprehensive diagnostic criteria for IgG4-RD are practically useful for general physicians and nonspecialists and have increased the sensitivity of diagnosis to 100% for Igg4-related MD, KD, and AIP.
Abstract: IgG4-related disease (IgG4-RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4+ plasma cells Although IgG4-RD is not rare and is clinically important, its clinical diagnostic criteria have not been established Comprehensive diagnostic criteria for IgG4-RD, including the involvement of various organs, are intended for the practical use of general physicians and nonspecialists Two IgG4-RD study groups, the Umehara and Okazaki teams, were organized by the Ministry of Health, Labor and Welfare Japan As IgG4-RD comprises a wide variety of diseases, these groups consist of physicians and researchers in various disciplines, including rheumatology, hematology, gastroenterology, nephrology, pulmonology, ophthalmology, odontology, pathology, statistics, and basic and molecular immunology throughout Japan, with 66 and 56 members of the Umehara and Okazaki teams, respectively Collaborations of the two study groups involved detailed analyses of clinical symptoms, laboratory results, and biopsy specimens of patients with IgG4-RD, resulting in the establishment of comprehensive diagnostic criteria for IgG4-RD Although many patients with IgG4-RD have lesions in several organs, either synchronously or metachronously, and the pathological features of each organ differ, consensus has been reached on two diagnostic criteria for IgG4RD: (1) serum IgG4 concentration >135 mg/dl, and (2) >40% of IgG+ plasma cells being IgG4+ and >10 cells/high powered field of biopsy sample Although the comprehensive diagnostic criteria are not sufficiently sensitive for the diagnosis of type 1 IgG4-related autoimmune pancreatitis (IgG4-related AIP), they are adequately sensitive for IgG4-related Mikulicz’s disease (MD) and kidney disease (KD) In addition, the comprehensive diagnostic criteria, combined with organ-specific diagnostic criteria, have increased the sensitivity of diagnosis to 100% for IgG4-related MD, KD, and AIP Our comprehensive diagnostic criteria for IgG4-RD are practically useful for general physicians and nonspecialists
1,417 citations
Authors
Showing all 488 results
Name | H-index | Papers | Citations |
---|---|---|---|
Masakazu Toi | 69 | 578 | 23200 |
Terumi Kamisawa | 69 | 381 | 21586 |
Kei Ito | 50 | 123 | 11529 |
Hisashi Sakamaki | 46 | 372 | 9491 |
Morio Koike | 45 | 127 | 9541 |
Naoto Egawa | 40 | 169 | 6276 |
Michiko Miyaki | 38 | 96 | 6645 |
Yutaka Yamamoto | 36 | 171 | 2980 |
Nobuaki Funata | 34 | 113 | 5335 |
Takeshi Tominaga | 33 | 149 | 5003 |
Katsumasa Kuroi | 33 | 145 | 4649 |
Shinsuke Ishigaki | 33 | 76 | 4457 |
Hideki Akiyama | 32 | 126 | 5653 |
Emi Nakashima | 31 | 141 | 3691 |
Goro Honda | 31 | 114 | 3575 |